Adenovirus vectors hold around 24% contribution in the gene therapy treatment trials being pursued by industry participants, says RNCOS.
(prHWY.com) April 26, 2012 - NOIDA, India -- In less than a couple of decades, gene therapy has strengthened dynamically, both in terms of scientific and technological advances. The gene therapy market also progressed to the advanced clinical trials stages in key therapeutic conditions. In 2011, the global gene therapy market is estimated to have reached around US$ 485 Million and is further expected to grow significantly with the introduction of new products in developed countries. However, it will take 4-6 years before the market could attain an optimum level of success (anticipated approval of Glybera may positively impact the market in a significant manner). The market is anticipated to reach the mark of US$ 650 Million by the end of 2015, as per the latest report by RNCOS "Global Gene Therapy Market Analysis".
The report has found that adenovirus vectors hold a leading position in the ongoing gene therapy clinical studies. Its usage rate is around 24% in the gene therapy treatment trials being pursued by industry participants. Companies, such as Applied Genetic Technologies, Amsterdam Molecular, Genzyme, GenVec, etc are conducting trials for gene therapy-based products using adenovirus vectors.
The report, which is spread in over 120-page, analyzes the usage of key vectors and leading technologies in gene therapy market landscape and thereby, gauges opportunities for industry players. The report also takes into account almost all the key aspects of the market and investigates the trends that may have an impact on the sector profitability or future development. Moreover, the report incorporates the information on advanced gene therapy drugs and the recent industry developments to provide a balanced outlook on the market potentials.
The report is an outcome of an extensive research and prudent analysis of the global gene therapy market that depicts the most unbiased picture of global gene therapy market. The report also presents forecasts for the industry, projecting the potential market to be generated by key gene therapy products to be launched in future. With the co-ordination of all the factors, we have presented a coherent analysis of the performance of the concerned industry.
For FREE SAMPLE of this report visit:
http://www.rncos.com/Report/IM282.htm
Some of our Related Reports are:
- Cancer Monoclonal Antibodies Market to 2015 (
http://www.rncos.com/Report/IM375.htm)
- Global Biosimilars Market Forecast to 2015 (
http://www.rncos.com/Report/IM379.htm)
- US Biotech Market Analysis (
http://www.rncos.com/Report/IM0300.htm)
- Global miRNA Market Outlook (
http://www.rncos.com/Report/IM286.htm)
- Global HIV Therapeutics Market Analysis (
http://www.rncos.com/Report/IM361.htm)
Check Related REPORTS on:
http://www.rncos.com/Healthcare_Industry.htm
About RNCOS
RNCOS specializes in Industry intelligence and creative solutions for contemporary business segments. Our professionals analyze the industry and its various components, with a comprehensive study of the changing market behavior. Our accuracy and data precision proves beneficial in terms of pricing and time management that assist the intending consultants in meeting their objectives in a cost-effective and timely manner.
###